(#$QNRX) got FDA conditional approval for QYLEKI as the brand name for QRX003, its topical treatment for Netherton Syndrome, moving it closer to Phase 3 and a potential first‑in‑disease NDA.
#QuoinPharma #NethertonSyndrome #QRX003
prismmarketview.com/quoin-pharma...

We speak with Azitra’s COO Travis Whitfill about EGFRi associated rash and the rationale behind ATR-04.
$AZTR
#Azitra #NethertonSyndrome #RareDisease

#QNRX just got the green light from the FDA to launch its second pivotal trial of QRX003 for Netherton Syndrome.
#QuoinPharma #NethertonSyndrome.

prismmarketview.com/quoin-pharma...

#QNRX Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...